Product Description
Metronidazole is one of the mainstay drugs for the treatment of anaerobic bacterial infections, protozoal infections, and microaerophilic bacterial infections. It is cytotoxic to facultative anaerobic microorganism. Metronidazole diffuses into the organism, inhibits protein synthesis by interacting with DNA and causing a loss of helical DNA structure and strand breakage. Therefore, it causes cell death in susceptible organisms. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK539728/)
Mechanisms of Action: Nucleic Acid Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral, Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: Eastern America
Company Founding Year: 1849
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China, France, India, Romania, Spain, United States
Active Clinical Trial Count: 12
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Candidiasis, Vulvovaginal|Hidradenitis Suppurativa|Pneumonia, Ventilator-Associated|Vaginal Discharge|Vaginitis|Vaginosis, Bacterial
Phase 2: Diverticulitis|Other
Phase 1: Atrial Fibrillation|Clostridium Infections|Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07146217 |
ATI-1501-0X | P2 |
Not yet recruiting |
Other |
2026-07-01 |
12% |
2025-08-29 |
|
NCT05821478 |
ABCESS2 | P3 |
Recruiting |
Hidradenitis Suppurativa |
2027-02-28 |
16% |
2025-07-10 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
2024-518862-28-00 |
NNMAIS 01/2021 | P3 |
Temporary halt |
Vaginosis, Bacterial|Candidiasis, Vulvovaginal |
2026-07-01 |
2025-05-02 |
Treatments |
|
2017-002742-68 |
2017-002742-68 | P3 |
Completed |
Pneumonia, Ventilator-Associated |
2023-02-23 |
41% |
2025-07-08 |
Treatments |
2023-506224-87-00 |
DIREBIOT | P2 |
Recruiting |
Diverticulitis |
2025-12-31 |
2025-05-02 |
Treatments |
|
NCT07251127 |
GP-MTZ DR-25-0527 | P1 |
Completed |
Clostridium Infections |
2025-06-06 |
2025-11-27 |
Primary Endpoints|Treatments |
|
CTR20131052 |
CTR20131052 | P3 |
Recruiting |
Vaginal Discharge|Vaginitis |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
NCT06806995 |
W-5222-106 | P1 |
Completed |
Healthy Volunteers |
2025-02-17 |
12% |
2025-09-04 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
ACTRN12625000283471 |
ACTRN12625000283471 | P1 |
Recruiting |
Vaginosis, Bacterial |
None |
2026-01-31 |
||
ACTRN12620000461998p |
2006-7041-83/hah | P1 |
Not yet recruiting |
Atrial Fibrillation |
None |
|||
CTR20240497 |
CTR20240497 | P2 |
Completed |
Vaginosis, Bacterial |
2024-12-25 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
2021-006991-18 |
FRENCH24 ANIS | P3 |
Active, not recruiting |
Unknown |
2025-04-03 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/21/2026 |
News Article |
Primera Professional Pharmacy Introduces the Demovectin™ Kit |
|
12/18/2025 |
News Article |
Appili Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement |
|
11/12/2025 |
News Article |
The Lundquist Institute and Its Start-Up Company Vitalex Biosciences Announce Strategic Advancement of Second-Generation Fungal Vaccine VXV-01 Through Phase 1 Trials Under $40 Million Competitive Contract From NIH/NIAID |
|
11/05/2025 |
News Article |
Appili Therapeutics Announces Proposed Non-Brokered Private Placement |